Related Experiment Video
Updated: Jun 25, 2026

Closed-Loop Neurostimulation for Biomarker-Driven, Personalized Treatment of Major Depressive Disorder
Published on: July 7, 2023
An update on the treatment of bipolar depression
Jean-Michel Azorin1, Arthur Kaladjian
1Pôle Universitaire de Psychiatrie-Solaris, Hôpital Ste Marguerite, 13274 Marseille Cedex 9, France. jazorin@ap-hm.fr
Background:
Although depression accounts for a large part of the burden associated with bipolar disorder, its drug treatment has been under-studied.
Objective:
To provide the best available evidence supporting the pharmacotherapy of bipolar depression.
Methods:
A systematic review was conducted, focusing on randomized, controlled trials (RCTs) and meta-analyses.
Results/Conclusions:
Despite FDA approval of both the olanzapine-fluoxetine combination and quetiapine for the treatment of acute bipolar depression, independent RCTs (i.e., not trials conducted 'under the umbrella' of a drug company) have not found any drug to have antidepressant effects similar to those seen in unipolar depression. A practice-based suggestion, valuable for both short- and long-term treatment, might be to have a background of mood stabilizers and to add drugs, following one of several treatment options, trusting to find a drug with a degree of effectiveness by trial and error. The list of drugs that could be used would include all the current antidepressants, the olanzapine-fluoxetine combination and probably quetiapine too. Special features and situations might also influence treatment options.
Related Concept Videos
Mania and Antimanic Drugs: Overview
Bipolar Disorder
Drug Therapy
Antianxiety Medications
Psychosis: Goals of Pharmacotherapy
Antidepressant Drugs: MAOIs and Other Agents
Electroconvulsive Therapy